EMCOR Group Inc (EME)vsSanofi ADR (SNY)
EME
EMCOR Group Inc
$817.44
-3.31%
INDUSTRIALS · Cap: $36.65B
SNY
Sanofi ADR
$44.38
+4.74%
HEALTHCARE · Cap: $104.85B
Smart Verdict
WallStSmart Research — data-driven comparison
Sanofi ADR generates 167% more annual revenue ($47.35B vs $17.75B). SNY leads profitability with a 16.0% profit margin vs 7.5%. EME appears more attractively valued with a PEG of 0.44. EME earns a higher WallStSmart Score of 66/100 (B-).
EME
Strong Buy66
out of 100
Grade: B-
SNY
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for EME.
Margin of Safety
+5.5%
Fair Value
$49.78
Current Price
$44.38
$5.40 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 35 in profit
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
19.7% revenue growth
Earnings expanding 30.0% YoY
Reasonable price relative to book value
Large-cap with strong market position
Conservative balance sheet, low leverage
Strong operational efficiency at 20.0%
Generating 1.7B in free cash flow
Areas to Watch
Moderate valuation
Trading at 9.4x book value
7.5% margin — thin
Negative free cash flow — burning cash
Expensive relative to growth rate
Earnings declined 11.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : EME
The strongest argument for EME centers on PEG Ratio, Return on Equity, Altman Z-Score. Revenue growth of 19.7% demonstrates continued momentum. PEG of 0.44 suggests the stock is reasonably priced for its growth.
Bull Case : SNY
The strongest argument for SNY centers on Price/Book, Market Cap, Debt/Equity. Profitability is solid with margins at 16.0% and operating margin at 20.0%.
Bear Case : EME
The primary concerns for EME are P/E Ratio, Price/Book, Profit Margin.
Bear Case : SNY
The primary concerns for SNY are PEG Ratio, EPS Growth.
Key Dynamics to Monitor
EME profiles as a growth stock while SNY is a mature play — different risk/reward profiles.
EME carries more volatility with a beta of 1.12 — expect wider price swings.
EME is growing revenue faster at 19.7% — sustainability is the question.
SNY generates stronger free cash flow (1.7B), providing more financial flexibility.
Bottom Line
EME scores higher overall (66/100 vs 51/100) and 19.7% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
EMCOR Group Inc
INDUSTRIALS · ENGINEERING & CONSTRUCTION · USA
EMCOR Group, Inc. provides electrical and mechanical installation and construction services in the United States. The company is headquartered in Norwalk, Connecticut.
Sanofi ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.
Compare with Other ENGINEERING & CONSTRUCTION Stocks
Want to dig deeper into these stocks?